Fmr LLC trimmed its position in shares of Dermira, Inc. (NASDAQ:DERM) by 15.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,720,950 shares of the biopharmaceutical company’s stock after selling 495,589 shares during the period. Fmr LLC owned about 6.55% of Dermira worth $79,288,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. BNP Paribas Arbitrage SA raised its holdings in shares of Dermira by 2,220.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 3,975 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Dermira by 66.8% during the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 2,203 shares in the last quarter. KCG Holdings Inc. purchased a new position in shares of Dermira during the 1st quarter valued at about $215,000. Legal & General Group Plc raised its holdings in shares of Dermira by 16.3% during the 1st quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 963 shares in the last quarter. Finally, American International Group Inc. raised its holdings in shares of Dermira by 23.4% during the 1st quarter. American International Group Inc. now owns 14,900 shares of the biopharmaceutical company’s stock valued at $508,000 after buying an additional 2,829 shares in the last quarter. 97.56% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Fmr LLC Decreases Position in Dermira, Inc. (DERM)” was originally published by Markets Daily and is owned by of Markets Daily. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.themarketsdaily.com/2017/10/13/fmr-llc-decreases-position-in-dermira-inc-derm.html.
A number of equities analysts recently weighed in on DERM shares. BidaskClub raised Dermira from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Cantor Fitzgerald started coverage on Dermira in a report on Thursday, June 22nd. They set an “overweight” rating and a $45.00 price objective on the stock. Evercore ISI started coverage on Dermira in a report on Thursday, June 29th. They set an “outperform” rating and a $48.00 price objective on the stock. Needham & Company LLC reissued a “buy” rating and set a $46.00 price objective on shares of Dermira in a report on Tuesday, July 18th. Finally, Zacks Investment Research cut Dermira from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Four investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $44.40.
Dermira (NASDAQ:DERM) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.04). Dermira had a negative net margin of 408.50% and a negative return on equity of 31.66%. The firm had revenue of $1.07 million for the quarter, compared to the consensus estimate of $1.00 million.
In related news, Director Fred B. Craves acquired 30,000 shares of the stock in a transaction dated Monday, August 14th. The stock was acquired at an average cost of $23.03 per share, with a total value of $690,900.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Thomas G. Wiggans sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 10th. The shares were sold at an average price of $27.52, for a total value of $137,600.00. The disclosure for this sale can be found here. Insiders sold a total of 16,800 shares of company stock valued at $457,351 over the last ninety days. Corporate insiders own 13.30% of the company’s stock.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.